Detailed explanation of the contents of the drug instructions and medication operation instructions of Ixazomib (Enleri)

Ixazomib (trade name Ninlaro) is an oral reversible proteasome inhibitor, mainly used for the treatment of patients with multiple myeloma (MM), especially in combination with lenalidomide ( Lenalidomide) and dexamethasone (Dexamethasone) are used in combination for patients with relapsed or refractory multiple myeloma who have received at least first-line therapy in the past. Ixazomib inhibits the activity of 26S proteasome and blocks the protein degradation pathway of tumor cells, leading to tumor cell apoptosis and inhibition of proliferation, thereby delaying disease progression. The emergence of oral preparations eliminates the need for patients to frequently go to the hospital for intravenous treatment, improving convenience and compliance.

According to the instructions, ixazomib is usually taken orally once a week, and the recommended dose is 4 mg/ times. It is best to take it at a fixed time. The medicine should be swallowed whole and should not be crushed, chewed or dissolved to avoid affecting drug absorption. Patients should take the medicine on an empty stomach. It is recommended to take it at least one hour before or after eating, with sufficient water to ensure full absorption of the medicine. If a dose is missed, it should be taken as soon as possible on the same day. If it is close to the time of the next dose, the missed dose should be skipped. Never take a double dose at one time. In addition, patients should strictly follow the course of treatment under the guidance of a doctor and are not allowed to adjust the dosage or stop taking the medicine on their own to ensure the efficacy.

Ixazomib is mainly metabolized through the liverCYP3A pathway, so co-administration with potent CYP3A inhibitors or inducers may affect blood concentration, increase the risk of toxicity or reduce efficacy. Patients should truthfully report all concomitant medications, including over-the-counter drugs, supplements and herbal medicines, to their doctors during medication to avoid drug interactions. Contraindications include those who are allergic to ixazomib or preparation excipients, and pregnant or lactating women. In addition, patients with severe liver function impairment should use it with caution and adjust the dosage under the guidance of a doctor.

Common adverse reactions of ixazomib include gastrointestinal symptoms (such as diarrhea, nausea, vomiting), hematological abnormalities (such as thrombocytopenia, neutropenia), fatigue and peripheral neuropathy. Most side effects are mild to moderate and can be alleviated through symptomatic treatment, dose adjustment, or temporary discontinuation of the drug. If serious hematological abnormalities occur, the blood routine should be reviewed promptly and dosage adjustment or supportive treatment should be performed under the guidance of a doctor. For peripheral neuropathy, vitamin B family or neuroprotective measures can be taken, and the drug dosage can be adjusted if necessary. Regular follow-up and monitoring of blood indicators and liver and kidney functions can help detect potential risks in time.

During home management, patients should maintain a healthy routine and a balanced diet, avoid contact with sources of infection, and especially when hematological indicators decline, protection should be strengthened. When taking medication, the daily medication time and adverse reactions should be recorded to facilitate doctor follow-up and dosage adjustment. Patients can take rest, diet adjustment or symptomatic treatment when experiencing mild discomfort, but if fever, severe fatigue or bleeding occur, they should contact a doctor immediately. Alcohol consumption and the use of drugs that may affect liver function should be avoided to reduce the risk of drug toxicity.

Ixazomib is a long-term maintenance treatment drug. Patients should undergo regular review under the guidance of a doctor, including blood routine, liver and kidney function, bone marrow indicators and imaging evaluation, to judge the efficacy and monitor adverse reactions. Long-term use can effectively prolong progression-free survival, but changes in hematology and liver function must be paid close attention to. If the disease shows signs of drug resistance or progression, the treatment plan should be adjusted under the guidance of a doctor or combined with other drugs to maintain efficacy and safety.

Overall, ixazomib is an oral proteasome inhibitor that provides a convenient targeted treatment option for patients with multiple myeloma. Patients should strictly follow the doctor's instructions during use, take it at a fixed dose and time, review blood routine and liver and kidney function regularly, and deal with adverse reactions in a timely manner. Through scientific management, close cooperation between doctors and patients, and standardized medication use, the efficacy can be maximized while ensuring safety, and patients can be provided with a sustained and effective disease control plan.

Reference materials:https://www.drugs.com/